Ontology highlight
ABSTRACT:
SUBMITTER: Zhu Q
PROVIDER: S-EPMC3072724 | biostudies-literature | 2011 Mar
REPOSITORIES: biostudies-literature
Zhu Qing Q McAuliffe Josie M JM Patel Nita K NK Palmer-Hill Frances J FJ Yang Chin-fen CF Liang Brandon B Su Lan L Zhu Wei W Wachter Leslie L Wilson Susan S MacGill Randall S RS Krishnan Subramaniam S McCarthy Michael P MP Losonsky Genevieve A GA Suzich JoAnn A JA
The Journal of infectious diseases 20110105 5
<h4>Background</h4>Palivizumab is a US Food and Drug Administration-approved monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory disease in high-risk infants. Motavizumab, derived from palivizumab with enhanced antiviral activity, has recently been tested in humans. Although palivizumab escape mutants have been generated in the laboratory, the development of resistant RSV in patients receiving palivizumab has not been reported previously.<h4>Methods</h4> ...[more]